Clinical Trials

MainTitle

Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG)

This study has been completed
Sponsor
St Stephens Aids Trust


Information provided by (Responsible Party)
St Stephens Aids Trust
ClinicalTrials.gov Identifier
NCT02098837

First received: March 20, 2014
Last updated: April 6, 2018
Last Verified: April 2018
History of Changes
Purpose

Purpose

The purpose of the study is to investigate the benefits of switching away from a kind of drug called a boosted protease inhibitor (PI) to a new drug called dolutegravir on patients' cardiovascular health (the health of their hearts). Patients are currently taking two other anti-HIV drugs, called nucleoside reverse transcriptase inhibitors (NRTIs), with their boosted PIs; these NRTIs will not be changed throughout the study. In order to compare the boosted PI and dolutegravir more accurately, half of study participants will be switched to dolutegravir immediately, and the other half will be switched after 48 weeks of continuing on the boosted PI.

Boosted PIs are associated with increased heart and circulation risk so it is hoped that switching from a boosted PI to dolutegravir will improve the health of the patients' hearts. Dolutegravir is a drug for HIV treatment which has been approved for use in HIV patients in the US and Europe. Clinical trials using dolutegravir have found that it is effective at suppressing the HIV virus, and it is at least as effective as the other drugs.

This study will also investigate the safety (in terms of other side effects and the routine blood tests which the investigators ordinarily use to monitor patients' treatment) and monitor effectiveness, patients' viral load and CD4 counts, when patients switch treatment from a boosted PI to dolutegravir. Viral load is the amount of the HIV virus they have in their blood, and CD4 count is a measure of a type of cell that is in their immune system. We also aim to improve patients' cardiovascular health in general by providing them with information on how to live a healthy lifestyle (eg improving their diet, stopping smoking etc).

Condition Intervention Phase
HIV

Drug : Dolutegravir
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Study Examining the Efficacy and Cardiovascular Risk of Immediate Versus Deferred Switch From a Boosted PI to Dolutegravir (DTG) in HIV Infected Patients With Stable Virological Suppression

Further study details as provided by St Stephens Aids Trust:

Primary Outcome Measures

  • Virological suppression [ Time Frame: 48 weeks ]
    Maintenance of virological suppression (ie HIV-1 RNA <50 c/ml) after 48 weeks
  • Total cholesterol [ Time Frame: 48 weeks ]
    Change from baseline in total cholesterol at week 48
Secondary Outcome Measures:
  • Virological Suppression [ Time Frame: 24 - 96 weeks ]
    Maintenance of virological suppression (ie HIV-1 RNA <50 c/ml) at week 24 and 96
  • CD4 count from baseline [ Time Frame: 24 - 96 weeks ]
    Change in CD4 count from baseline to week 24, 48 and 96
  • Baseline in total cholesterol [ Time Frame: 24 - 96 weeks ]
    Change from baseline in total cholesterol at weeks 24 and 96
  • Change from baseline to lipid values [ Time Frame: 24 - 96 weeks ]
    Change from baseline to lipid values (LDL, HDL, triglycerides and TC:HDL ratio) and Framingham and DAD scores at weeks 24, 48 and 96
  • Safety [ Time Frame: 24 - 96 weeks ]
    Safety (clinical and laboratory adverse events) at weeks 24, 48 and 96
  • Changes in markers of inflammation [ Time Frame: 48 - 96 weeks ]
    Changes in markers of inflammation at baseline, week 48 and week 96
  • Tolerability [ Time Frame: 24 - 96 weeks ]
    Tolerability (EuroQoL questionnaire) at weeks 24, 48 and 96
  • Changes in markers of coagulation [ Time Frame: 48 - 96 weeks ]
    Changes in markers of coagulation at baseline, week 48 and week 96
  • Changes in markers of endothelial dysfunction [ Time Frame: 48 - 96 weeks ]
    Changes in markers of endothelial dysfunction at baseline, week 48 and week 96
  • Change to arterial stiffness augmentation index at weeks 48 and 96 [ Time Frame: 48 - 96 weeks ]
    Change from baseline to arterial stiffness augmentation index at weeks 48 and 96
  • Change to average thickness of common carotid artery walls at weeks 48 and 96 [ Time Frame: 48 - 96 weeks ]
    Change from baseline to average thickness of common carotid artery walls at weeks 48 and 96

Enrollment: 415
Study Start Date: April 2014
Study Completion Date: December 4, 2017
Primary Completion Date: November 2017 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Active Comparator: Immediate switch
Patients will be randomised to switch from a boosted PI to dolutegravir at baseline.
Drug: Dolutegravir

Dolutegravir 50mg once daily

Other Name: Tivicay
Active Comparator: Deferred switch
Patients will be randomised to switch from a boosted PI to dolutegravir after 48 weeks.
Drug: Dolutegravir

Dolutegravir 50mg once daily

Other Name: Tivicay

Detailed Description:

Study Design: Randomised, non-inferiority strategic trial over 96 weeks with early or delayed switch from an ARV regimen containing a boosted PI plus 2 NRTIs to dolutegravir (DTG) plus 2 NRTIs in patients having achieved complete virological suppression for more than 24 weeks (HIV-1 RNA <50 c/ml). Patients will be randomised to switch at baseline or at 48 weeks.
Study visits will take place at screening, baseline, weeks 4 (immediate switch group only), 12, 24, 36, 48, 52 (deferred switch group only), 60, 72, 84 and 96, plus a follow up visit 28 days after the last dose of study medication.
Routine investigations will include viral load, CD4, haematology (including haemoglobin, white cell count and differential, platelets), biochemistry (including sodium, potassium, creatinine, albumin, glucose, ALT, ALP, total bilirubin, total cholesterol, HDL, LDL, triglycerides), quality of life questionnaires (EuroQL), urine sample (for haematuria, proteinuria, glycosuria, leukocytes, nitrate & pregnancy test in WOCBP)

Eligibility

Eligibility

Ages Eligible for Study: 18 Years to 99 Years  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

Inclusion Criteria:

  • Patient volunteers who meet all of the following criteria are eligible for this trial:
    1. Is male or female aged over 50, OR aged over 18 years with a Framingham risk score above 10%
    2. Has documented HIV-1 infection
    3. Has signed the Informed Consent Form voluntarily
    4. Is willing to comply with the protocol requirements
    5. Has been receiving an ARV regimen containing a boosted PI (darunavir, atazanavir, lopinavir, or fosamprenavir) plus 2NRTIs for >24 weeks
    6. Has stable virological suppression (plasma HIV-RNA <50 copies/mL for >24 weeks)
    7. If female and of childbearing potential, is using effective birth control methods and is willing to continue practising these birth control methods during the trial and for at least 2 weeks after the last dose of study medication. Note: Non-childbearing potential is defined as either post-menopausal (12 months of spontaneous amenorrhoea and ≥45 years) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy
    8. If a heterosexually active male, he is using effective birth control methods and is willing to continue practising these birth control methods during the trial and until follow-up visit

  • Exclusion Criteria:
  • Patients meeting 1 or more of the following criteria cannot be selected:
    1. Infected with HIV-2
    2. Using any concomitant therapy disallowed as per the reference safety information and product labelling for the study drugs
    3. Has acute viral hepatitis including, but not limited to, A, B, or C
    4. Has chronic hepatitis B and/or C with AST and/or ALT >5 x ULN Note: Subjects can enter trial with chronic HBV if HBV-DNA undetectable at screen (and no detectable result in last 6 months) and with chronic HCV if not expected to require treatment during the trial period.
    5. Any investigational drug within 30 days prior to the trial drug administration
    6. History of exposure to any ARVs other than PIs or NRTIs except if switch was for tolerability/toxicity (NOTE: patients who have previously taken part in single drug trials for less than 14 days need not be excluded, or for virological failure with a genotypic resistance test without mutations
    7. Any prior evidence of primary viral resistance based on the presence of any major resistance-associated mutation to backbone NRTI
    8. History of prior virological failure,eg 2 consecutive HIV-1 RNA >50 c/ml -at or after week 32 following first ART initiation or confirmed rebound viraemia >200 copies/ml after having a VL of <50 copies/ml without resistance test or with significant mutations to any other ARV regimen (NOTE: Switch for toxicity or tolerability with wild type virus does not count as virological failure)
    9. Dialysis or renal insufficiency (creatinine clearance < 50ml/min)
    10. History of decompensated liver disease (AST or ALT≥5x the upper limit of normal (ULN) or ALT ≥ )3 x ULN and bilirubin ≥ 1.5 x ULN with > 35% direct bilirubin.
    11. Unstable liver disease (as defined by the presence of ascities, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), know biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones))
    12. Subjects with severe hepatic impairment (Class C) as determined by Child-Pugh classification
    13. If female, currently pregnant or breastfeeding
    14. Opportunistic infection within 4 weeks prior to first dose of DTG
    15. Clinical decision that a switch of antiretroviral therapy should be immediate
    16. Screening blood result with any grade 3/4 toxicity according to Division of AIDS (DAIDS) grading scale, except: asymptomatic grade 3 glucose, amylase or lipid elevation or asymptomatic grade 4 triglyceride elevation (re-test allowed).
    17. Any condition (including illicit drug use or alcohol abuse) or laboratory results which, in the investigator's opinion, interfere with assessments or completion of the trial.
    18. History or presence of allergy to the study drug or their components

    contacts and locations

    Contacts and Locations

    Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

    Please refer to this study by its ClinicalTrials.gov identifier: NCT02098837

    Locations

    Belgium
    Insititute Of Tropical Medicine Antwerp
    Antwerp, Belgium, B-2000
    CHU Saint-Pierre
    Brussels, Belgium, 100
    Universitaire Ziekenhuis Gent
    Gent, Belgium, 9000
    France
    Hopital de la Croix Rousse
    Lyon, France, 69004
    Service des Maladies Infectieuses et Tropicales du CHU de NANTES
    Nantes, France, 44093
    Hopital Saint Louis
    Paris, France, 75010
    Pitié-Salpêtrière Hospital
    Paris, France, 75013
    Hospital Bichat Claude-Bernard
    Paris, France, 75018
    Germany
    Universitätsklinikum Bonn
    Bonn, Germany, 53127
    Universitätsklinikum Essen
    Essen, Germany, 45147
    Klinikum der Goethe-Universität Frankfurt
    Frankfurt, Germany, 60590
    ICH Infektiologisches Centrum Hamburg
    Hamburg, Germany, 20146
    Medizinische Hochschule Hannover
    Hannover, Germany, 30625
    Italy
    Santa Maria Annunziata di Firenze
    Firenze, Italy, 50011
    San Paolo Hospital
    Milan, Italy, 20142
    Azienda Ospedaliera - Polo Universitario 'Luigi Sacco'
    Milan, Italy, 20157
    Universitaria di Modena
    Modena, Italy, 41124
    Spain
    Universitario Alicante
    Alicante, Spain, 03010
    Hospital General Universitario de Elche
    Alicante, Spain, 03203
    Hospital de la Santa Creu i Sant Pau
    Barcelona, Spain, 08025
    Hospital Clinic Barcelona
    Barcelona, Spain, 08036
    Universitari de Bellvitge
    Barcelona, Spain, 08907
    IrsiCaixa
    Barcelona, Spain, 08916
    Hospital Ramon y Cajal
    Madrid, Spain, 28034
    Hospital Universitario La Paz
    Madrid, Spain, 28046
    United Kingdom
    Elton John Centre
    Brighton, United Kingdom, BN2 1ES
    Southmead Hospital
    Bristol, United Kingdom, BS10 5NB
    Bart's Hospital
    London, United Kingdom, E1 1BB
    Royal Free Hospital
    London, United Kingdom, NW3 2QG
    St Thomas Hospital
    London, United Kingdom, SE1 7EH
    Chelsea & Westminster Hospital
    London, United Kingdom, Sw10 9NH
    St Mary's Hospital
    London, United Kingdom, W2 1NY
    Mortimer Market Centre
    London, United Kingdom, WC1E 6JB

    Sponsors and Collaborators

    St Stephens Aids Trust

    Investigators

    Principal Investigator: Jose Gatell, Dr Spanish healthcare system
    More Information

    More Information


    Responsible Party: St Stephens Aids Trust  
    ClinicalTrials.gov Identifier: NCT02098837   History of Changes  
    Other Study ID Numbers: NEAT 22/SSAT 060  
    Study First Received: March 20, 2014  
    Last Updated: April 6, 2018  
    Individual Participant Data    
    Plan to Share IPD: Undecided  

    Keywords provided by St Stephens Aids Trust:

    HIV

    Additional relevant MeSH terms:
    Dolutegravir

    ClinicalTrials.gov processed this data on June 02, 2020
    This information is provided by ClinicalTrials.gov.